作为侵袭性较低的乳腺癌患者的辅助预后因素：一项文献综述研究

as an Adjunct Prognostic Factor in Breast Cancer Patients with Less Aggressive Disease: A Study with a Review of the Literature.

作者信息

Querzoli Patrizia, Pedriali Massimo, Rinaldi Rosa, Secchiero Paola, Rossi Paolo Giorgi, Kuhn Elisabetta

机构信息

Section of Anatomic Pathology, Department of Morphology, Surgery and Experimental Medicine, University of Ferrara, 44124 Ferrara, Italy.

Section of Anatomic Pathology, ASST Mantova, Ospedale Carlo Poma, 46100 Mantova, Italy.

出版信息

Diagnostics (Basel). 2021 Mar 28;11(4):604. doi: 10.3390/diagnostics11040604.

BACKGROUND

GATA binding protein 3 () expression is positively correlated with estrogen receptor (ER) expression, but its prognostic value as an independent factor remains unclear. Thus, we undertook the current study to evaluate the expression of and its prognostic value in a large series of breast carcinomas (BCs) with long-term follow-up.

METHODS

A total of 702 consecutive primary invasive BCs resected between 1989 and 1993 in our institution were arranged in tissue microarrays, immunostained for ER, progesterone receptor (PR), ki-67, HER2, p53, and , and scored. Clinico-pathological data were retrospectively collected.

RESULTS

was evaluable in 608 (87%) of the 702 cases; it was positive in 413 (68%) cases and negative in 195 (32%) cases. positivity was significantly associated with lower grade ( < 0.0001), size ( = 0.0463), stage ( = 0.0049), ER+ ( < 0.0001), PR+ ( < 0.0001), HER2- ( = 0.0175), and p53 wild-type pattern ( < 0.0001). The median follow-up was 183 months, positivity was associated with better overall survival (HR 0.70, = 0.001), and its prognostic value was retained in a multivariate analysis. The association with better overall survival was stronger in patients with grade 1-2, pT1-2, pN0, stage I-II, ER+, PR+, ki-67 < 20%, HER2-, a wild-type p53 immunohistochemical pattern, and in luminal B BC.

CONCLUSIONS

Our findings indicate that is a positive prognostic marker in BC patients, especially in patients with biologically less aggressive BC. Incorporating immunohistochemistry into routine practice could help further stratify BC patients for their risk.

背景

GATA结合蛋白3（）的表达与雌激素受体（ER）的表达呈正相关，但其作为独立因素的预后价值仍不明确。因此，我们开展了本研究，以评估在一系列接受长期随访的乳腺癌（BC）中的表达及其预后价值。

方法

将1989年至1993年在我院连续切除的702例原发性浸润性BC制成组织芯片，进行ER、孕激素受体（PR）、ki-67、HER2、p53和的免疫染色并评分。回顾性收集临床病理数据。

结果

702例病例中有608例（87%）可评估；其中413例（68%）为阳性，195例（32%）为阴性。阳性与低分级（ < 0.0001）、肿瘤大小（ = 0.0463）、分期（ = 0.0049）、ER阳性（ < 0.0001）、PR阳性（ < 0.0001）、HER2阴性（ = 0.0175）及p53野生型模式（ < 0.0001）显著相关。中位随访时间为183个月，阳性与更好的总生存期相关（HR 0.70， = 0.001），且其预后价值在多因素分析中得以保留。在1 - 2级、pT1 - 2、pN0、I - II期、ER阳性、PR阳性、ki-67 < 20%、HER2阴性、p53免疫组化野生型模式的患者以及管腔B型BC患者中，与更好的总生存期的关联更强。